The Highly Selective Caspase-1 Inhibitor VX-765 Provides Additive Protection Against Myocardial Infarction in Rat Hearts When Combined with a Platelet Inhibitor

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 22, Issue 6, 2017, Pages 574-578

  Yang, Xi Ming ^a   Downey, James M ^a   Cohen, Michael V ^a,b   Housley, Nicole A ^b   Alvarez, Diego F ^a,b   Audia, Jonathon P ^b  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

heart disease; ischemia reperfusion injury

Indexed keywords

BELNACASAN; CANGRELOR; INTERLEUKIN 1BETA CONVERTING ENZYME; MICROSPHERE; TETRAZOLIUM; 1-(2-((1-(4-AMINO-3-CHLOROPHENYL)METHANOYL)AMINO)-3,3-DIMETHYLBUTANOYL)PYRROLIDINE-2-CARBOXYLIC ACID; 4 AMINOBENZOIC ACID DERIVATIVE; ANTITHROMBOCYTIC AGENT; CARDIOTONIC AGENT; DIPEPTIDE; INTERLEUKIN-1BETA-CONVERTING ENZYME INHIBITOR; SERINE PROTEINASE INHIBITOR; VIRAL PROTEIN;

ACUTE HEART INFARCTION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; ENZYME INHIBITION; FLUORESCENCE ANALYSIS; HEART INFARCTION SIZE; HEART PROTECTION; MALE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; ANIMAL; BLOOD; COMBINATION DRUG THERAPY; DRUG EFFECT; HEART; HEART INFARCTION; ISOLATED HEART; PATHOPHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMALS; CARDIOTONIC AGENTS; DIPEPTIDES; DRUG THERAPY, COMBINATION; HEART; ISOLATED HEART PREPARATION; MALE; MYOCARDIAL INFARCTION; PARA-AMINOBENZOATES; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SERPINS; VIRAL PROTEINS;

EID: 85029913554     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248417702890     Document Type: Article

References (17)

1. Favaretto E, Roffi M, Frigo AC, et al. Meta-analysis of randomized trials of postconditioning in ST-elevation myocardial infarction. Am J Cardiol. 2014; 114 (6): 946-952.
2. Iliodromitis EK, Cohen MV, Dagres N, Andreadou I, Kremastinos DT, Downey JM,. What is wrong with cardiac conditioning? We may be shooting at moving targets. J Cardiovasc Pharmacol Ther. 2015; 20 (4): 357-369.
3. Cung TT, Morel O, Cayla G, et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med. 2015; 373 (11): 1021-1031.
4. 12 blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther. 2013; 18 (3): 251-262.
5. Yang XM, Cui L, White J, et al. Mitochondrially targeted Endonuclease III has a powerful anti-infarct effect in an in vivo rat model of myocardial ischemia/reperfusion. Basic Res Cardiol. 2015; 110 (2): 3.
6. Bliksøen M, Mariero LH, Torp MK, et al. Extracellular mtDNA activates NF-ΰB via toll-like receptor 9 and induces cell death in cardiomyocytes. Basic Res Cardiol. 2016; 111 (4): 42.
7. Man SM, Karki R, Kanneganti TD,. DNA-sensing inflammasomes: regulation of bacterial host defense and the gut microbiota. Pathog Dis. 2016; 74 (4): ftw028.
8. Pomerantz BJ, Reznikov LL, Harken AH, Dinarello CA,. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1β. Proc Natl Acad Sci U S A. 2001; 98 (5): 2871-2876.
9. Holly TA, Drincic A, Byun Y, et al. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol. 1999; 31 (9): 1709-1715.
10. Syed FM, Hahn HS, Odley A, et al. Proapoptotic effects of caspase-1/interleukin-converting enzyme dominate in myocardial ischemia. Circ Res. 2005; 96 (10): 1103-1109.
11. Mocanu MM, Baxter GF, Yellon DM,. Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br J Pharmacol. 2000; 130 (2): 197-200.
12. Koshinuma S, Miyamae M, Kaneda K, Kotani J, Figueredo VM,. Combination of necroptosis and apoptosis inhibition enhances cardioprotection against myocardial ischemia-reperfusion injury. J Anesth. 2014; 28 (2): 235-241.
13. Wannamaker W, Davies R, Namchuk M, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R, 3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1β and IL-18. J Pharmacol Exp Ther. 2007; 321 (2): 509-516.
14. National Research Council. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington, DC: National Academies Press; 2011.
15. Yang XM, Cui L, Alhammouri A, Downey JM, Cohen MV,. Triple therapy greatly increases myocardial salvage during ischemia/reperfusion in the in situ rat heart. Cardiovasc Drugs Ther. 2013; 27 (5): 403-412.
16. Ye Y, Birnbaum GD, Perez-Polo JR, Nanhwan MK, Nylander S, Birnbaum Y,. Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol. 2015; 35 (8): 1805-1814.
17. Vilahur G, Gutiérrez M, Casani L, et al. Protective effects of ticagrelor on myocardial injury after infarction. Circulation. 2016; 134 (22): 1708-1719.